Comparative Pharmacology
Head-to-head clinical analysis: SERNIVO versus TOPICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SERNIVO versus TOPICORT.
SERNIVO vs TOPICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SERNIVO (clobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing production of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Apply a thin layer to affected area twice daily for up to 2 weeks.
Apply a thin film to the affected skin areas twice daily. Maximum adult dose: 50 g/week. Not for use on the face, axillae, or groin. Do not use under occlusive dressings.
None Documented
None Documented
Approximately 3 hours (parent drug); clinical duration extended via formulation.
Terminal elimination half-life: 2-4 hours for parent drug; clinical effect lasts longer due to receptor binding
Primarily renal excretion of inactive metabolites; <5% unchanged. Minor biliary/fecal elimination.
Renal (metabolites): ~75%; Fecal: ~25%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid